Abstract:Putu Yuliandari, 1 I Putu Bayu Mayura 2 1 Centre for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Bogor, West Java, Indonesia; 2 Department of Microbiology, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia Correspondence: Putu Yuliandari, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Jl. Raya Jakarta - Bogor Km. 46, Cibinong, Bogor, West Java, Indonesia, Email View the original paper by Dr Xiao and colleagues We have read the article by Xiao et al about "Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients". 1 This study investigates the impact of Helicobacter pylori infection on glucose metabolism, lipid metabolism, and inflammatory cytokines in patients with nonalcoholic fatty liver disease (MASLD). Nonalcoholic fatty liver disease, now known as metabolic-dysfunction-associated steatotic liver disease (MASLD), is a leading cause of chronic liver disease worldwide. The global prevalence of MASLD has been increasing over time, with a recent meta-analysis estimating that MASLD afflicts 32% of the adult population. 2 Since the initial report of H. pylori DNA being detected in the liver of non alcoholic fatty liver disease patients, numerous studies have investigated the relationship between H. pylori infection and this disease. 3 The authors have utilized diagnostic criteria from the "Prevention and Treatment Guidelines for Nonalcoholic Fatty Liver Disease" which may not be readily accessible to an international audience due to the language barrier. The retrospective nature of the study implies reliance on diagnostic standards that have since been updated, as noted in the June 2023 revision by Rinella et al. 4 The study's methodology, particularly the use of the 14C-urea breath test to diagnose H. pylori infection, has inherent limitations. Future investigations could enhance diagnostic accuracy through molecular techniques, such as PCR, to detect H. pylori and its virulence factors, including variations in the cytotoxin-associated gene A (Cag A) status. 3 There is a direct association between H. pylori infection and insulin resistance and dyslipidemia, both presently recognized as factors contributing to the development of MASLD. Several studies revealed a positive correlation between H. pylori infection and MASLD, similar to this study, while some clinical studies negate this conclusion. 3 This may be due to variability in H. pylori strains, inconsistent H. pylori diagnostic methods, updated MASLD diagnostic criteria, and regional differences in race, genetics, lifestyle, and dietary habits. A possible mechanism of interaction between H. pylori infection and MASLD involves fetuin-A or alpha 2-HS glycoprotein (AHSG). Higher serum fetuin-A levels in H. pylori-positive patients have been reported to correlate with impaired insulin sensitivity and glucose tolerance. 5 Fetuin-A also acts as an endogenous adaptor protein for free fatty acid-mediated activation of TLR4 in mice. This might reflect the presence of a broad panel of inflammatory mediators (c-reactive protein, TNF-α, IL-6, IL-1β) in patients suffering from H. pylori infection. 6 Future research should employ large-scale and multi-center randomized controlled trials to objectively and effectively assess the influence of H. pylori infection in MASLD patients. We acknowledge and appreciate this study's contribution to the field of hepatology and gastroenterology, highlighting the extragastric influence of H. pylori on metabolic diseases. It lays a foundation for future research to explore the relationships between H. pylori infection, metabolic dysregulation, and MASLD more deeply, potentially leading to improved patient outcomes. The authors would like to acknowledge all the researchers and Prof. Dr. Sunarno in the Center for Biomedical Research BRIN for their continuous support. The authors would also like to convey gratitude to the research team of Xiao et al for their valuable research report. The authors have disclosed no conflicts of interest in this communication. 1. Xiao Q, Wang R, Wu H, Kuang W, Meng W, Cheng Z. Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients. J Multidisciplinary Healthcare . 2024;17:1127–1135. doi:10.2147/JMDH.S453429 2. Teng MLP, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol . 2023;29(supp1):32–42. doi:10.3350/CMH.2022.036 -Abstract Truncated-

Letter: higher severe outcomes among Helicobacter pylori‐related lean patients with non‐alcoholic fatty liver disease and metabolic comorbidities

Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis.

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience

Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis

Characterization of Fecal Microbial Communities in Patients with Liver Cirrhosis.

Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome

Bidirectional relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: insights from a comprehensive meta-analysis

O-12 HELICOBACTER PYLORI VIRULENCE GENES ARE ASSOCIATED WITH NAFLD SEVERITY: A CROSS SECTIONAL STUDY IN DYSPEPTIC PATIENTS

Prospective cohort study of Helicobacter pylori infection on the risk of nonalcoholic fatty liver disease

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations with Gastrointestinal Symptoms

Long-term outcomes following hepatectomy in patients with lean non-alcoholic fatty liver disease-associated hepatocellular carcinoma versus overweight and obese counterparts: A multicenter analysis

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

Response to Article "Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients"

Helicobacter pylori infection is associated with liver fibrosis in patients with obesity undergoing bariatric surgery

Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD): A Cross-Sectional Study

High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis

Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study

Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease